Eltrombopag-induced liver dysfunction during the treatment of immune thrombocytopenia and its risk factors

Background: Eltrombopag is an effective oral thrombopoietin receptor agonist for the treatment of immune thrombocytopenia (ITP). A common adverse reaction is liver dysfunction. This study aimed to investigate early liver dysfunction during eltrombopag treatment of ITP and risk factors.